Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Rubitecan.

Jeffrey W Clark1

  • 1Hematology/Oncology, Massachusetts General Hospital, Boston, MA 02114, USA. jclark@partners.org

Expert Opinion on Investigational Drugs
|December 24, 2005
PubMed
Summary
This summary is machine-generated.

Rubitecan, an oral camptothecin analogue, shows promise for cancer treatment by inhibiting DNA topoisomerase I. While effective preclinically, clinical trials indicate significant activity primarily in pancreatic cancer.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neoadjuvant stereotactic body radiation therapy plus immune therapy favorably remodels the hepatocellular carcinoma tumor microenvironment.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibition in Patients With Metastatic Pancreatic Cancer.

JCO precision oncology·2025
Same author

Protected Time, Resources, and Expectations for Academic Oncology Clinical Research Physicians.

Journal of the National Comprehensive Cancer Network : JNCCN·2025
Same author

Long-term Outcomes of Definitive Chemoradiation With Proton Therapy for Treatment of Carcinoma of the Anal Canal: Combined Analysis of Two Prospective Trials.

International journal of radiation oncology, biology, physics·2025
Same author

Hypofractionated Radiotherapy-Related Lymphopenia Is Associated With Worse Survival in Unresectable Intrahepatic Cholangiocarcinoma.

American journal of clinical oncology·2024
Same author

Imaging of Neuroendocrine Neoplasms; Principles of Treatment Strategies. What Referring Clinicians Want to Know.

Journal of computer assisted tomography·2024
Same journal

Advancements in longevity pharmacology research - are we finally seeing clinical progression?

Expert opinion on investigational drugs·2026
Same journal

Consideration of the use of nalbuphine in idiopathic pulmonary fibrosis-associated cough: to cough or not to cough so much?

Expert opinion on investigational drugs·2026
Same journal

Investigational new drug TAP-1502 beginning clinical study for seborrheic dermatitis.

Expert opinion on investigational drugs·2026
Same journal

Cannabinoid use in adults with sickle cell disease: therapeutic development and clinical insights.

Expert opinion on investigational drugs·2026
Same journal

Odronextamab: a bispecific antibody for follicular lymphoma.

Expert opinion on investigational drugs·2026
Same journal

Evaluating the investigational drug landscape for <i>ESR1</i>-mutated, estrogen receptor-positive, HER2-negative metastatic breast cancer.

Expert opinion on investigational drugs·2026
See all related articles

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Approved camptothecins (topotecan, irinotecan) are intravenous, necessitating convenient oral alternatives.
  • Rubitecan is an orally available camptothecin analogue with potential for transdermal or inhaled delivery.
  • Camptothecins exert antitumour activity by inhibiting DNA topoisomerase I, crucial for DNA replication and transcription.

Purpose of the Study:

  • To evaluate the efficacy and pharmacokinetic variability of rubitecan, an oral camptothecin analogue.
  • To assess rubitecan's antitumour activity across various cancer types, comparing preclinical and clinical findings.

Main Methods:

  • Preclinical evaluation of rubitecan in vitro and in vivo human tumour xenograft models.
  • Phase I/II clinical trials assessing rubitecan's activity in patients with various solid tumours.

Related Experiment Videos

  • Analysis of rubitecan's equilibrium between 9-nitro-camptothecin (9-NC) and 9-amino-camptothecin (9-AC) and the role of the lactone ring.

    • Main Results:

    • Preclinical studies demonstrated broad-spectrum antitumour activity for rubitecan.
    • Clinical trials showed disappointing activity against most solid tumours, with notable exceptions in pancreatic and possibly ovarian cancers.
    • Lactone ring stability at physiological pH and pharmacokinetic variability presented development challenges.

    Conclusions:

    • Rubitecan exhibits promising preclinical antitumour activity but faces challenges in clinical translation.
    • Its efficacy is most pronounced in pancreatic cancer, warranting further clinical investigation for this indication.
    • Future clinical trials will determine rubitecan's definitive role in cancer therapy.